[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Ohnishi
Kazunori
K
D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D015473:Leukemia, Promyelocytic, Acute / Q000628:therapy*; D010087:Oxides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012074:Remission Induction; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D001565:Benzoates; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D010087:Oxides; D013764:Tetrahydronaphthalenes; C061133:tamibarotene; C012589:trichostatin A; D014212:Tretinoin; D000079982:Gemtuzumab; D000077237:Arsenic Trioxide